Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04609800
Recruitment Status : Withdrawn (Unfavorable opinion of IRB/IEC)
First Posted : October 30, 2020
Last Update Posted : December 21, 2020
Sponsor:
Information provided by (Responsible Party):
Ipsen

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : May 10, 2023
Estimated Study Completion Date : May 10, 2023